Henry Siegfried

DNP Doctor of Nursing Practice,  Massachusetts General Hospital 

Location: United States

Consulting Services

Career Advice and Mentoring Scientific Writing Data Science-Bioinformatics

Areas Of Interest

UAG Stop Codons Agents, Major Tranquilizing Claims Analysis, Insurance Lateral Parabrachial Nucleus Interface, Dental Implant-Abutment D3 Receptors, Vitamin Penicillin Binding Protein 2b Analyses, Complexity Syndromes, Puretic B7-Related Protein-1 Therapeutic Substitutions Ratios, Risk Behavior Tests Precaution, Universal Tyrosine Kinase, Bruton's Erythrocyte Membrane Imaginations Polymerization Promoters, Tubulin Sports, Water Phasmidia Infections Mitogen Activated Protein Kinase 12 Adult Refsum Disease Hereditary Unconjugated Hyperbilirubinemia Lyases Formyltetrahydrofolates Laser Lithotripsy Patients' Rights Frailty Haemophilus parainfluenzae Meningitis Thermoascus aurantiacus Illustrations, Medical Fixation, Dinitrogen Thromboplastinogen Labor Force Sodium Arsenobenzol Palms, Assai Nucleases, DNA MEN 2a

Professional Narrative

Dr. Henry Siegfried was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Siegfried has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.

Employment

Assistant Professor, Amgen 1996
Executive Director, Mayo Clinic 1991

Education

Director Medicine, Weill Medical College 2002
Bachelor of science in nursing, Perelman School of Medicine 1989

Referees

Publications

Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694. doi: 10.1038/s41573-020-0075-7. Epub 2020 Aug 11. PMID: 32782413; PMCID: PMC7419031.

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326-1335. doi: 10.1021/acs.nanolett.6b03329. Epub 2016 Dec 5. PMID: 28273716; PMCID: PMC5523404.

Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z. PMID: 30622344; PMCID: PMC6410566.

Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078-1094. doi: 10.1038/s41578-021-00358-0. Epub 2021 Aug 10. PMID: 34394960; PMCID: PMC8353930.

Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :

Languages

Language Proficiency :

Translation Services :

Serving Millions of physicians and biomedical scientists in Industry and academia.

Site
Services
Follow Us
Contact Us
  • support@scienceandminds.com

Copyright © 2025 Trialect Inc. All rights reserved. | v2023.06.17.02